AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2018
Feb 20, 2018
31580_dirs_2018-02-20_4613cbb3-fe40-4d20-a05f-70ac10f3bf0d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-02-16
Reporting Person: Hirsch Andrew (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-02-16 | Stock option (right to buy) | $77.70 | A | 33000 | Acquired | 2028-02-15 | Common stock (33000) | Direct |
| 2018-02-16 | Restricted stock units | $ | A | 8250 | Acquired | Common stock (8250) | Direct |
Footnotes
F1: This option was granted on February 16, 2018. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3: The restricted stock units were granted on February 16, 2018. The shares underlying the restricted stock units will vest in three equal annual installments on February 16, 2019, 2020 and 2021. Vested shares will be delivered to the reporting person within three business days after such shares become vested.